Key Time Stamps:

00:45 ~ CME Info

2:52 ~ Basics of BCMA- and GPRC5D-directed Therapies

4:45 ~ Rationale for FDA approval of elranatamab & teclistamab

5:08 ~ Safety of elranatamab & teclistamab

6:35 ~ Rationale for FDA approval of ide-cel & cilta-cel 

07:32 ~ Safety of ide-cel & cilta-cel 

9:00 ~ Treatment Selection: Case of 68yo African-American female, w/ Stage 2 MM w/ t(11:14) following progression after 4Lof therapy

14:00 ~ Treatment Selection: Case of 71yo White male, w/ Stage III MM with del17p following progression after 5L of therapy

18:25 ~ MonumenTAL-1 Study of talquetamab

19:43 ~ Toxicities associated with GPR5D-directed therapies

20:45 ~ Treatment selection w/ risk of infections: Case of 58yo Hispanic female, w/ Stage II MM w/o high-risk cytogenetics, following progression of 4L of therapy 

26:40 ~ Infection rates with BCMA-directed CAR-T Cells & Bispecific Antibodies

28:18 ~ Hematological toxicity with BCMA- and GPRC5D-directed therapies

29:09 ~ Hypogammaglobulinemia with BCMA- and GPRC5D-directed therapies

33:05 ~ Health disparities in MM

34:14 ~ Key differences with BCMA- and GPRC5D-directed therapies